Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
